Sponsor:
BeiGene
Code:
NCT06634589
Conditions
B-cell Malignancy
Relapsed Cancer
Refractory Cancer
B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BGB-16673
Sonrotoclax
Zanubrutinib
Mosunetuzumab
Glofitamab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by BeiGene on 2025-04-13.